Robert Chess - Sep 22, 2022 Form 4 Insider Report for NEKTAR THERAPEUTICS (NKTR)

Role
Director
Signature
Mark A. Wilson, Attorney-in-Fact
Stock symbol
NKTR
Transactions as of
Sep 22, 2022
Transactions value $
-$16,269
Form type
4
Date filed
9/26/2022, 07:23 PM
Previous filing
Sep 20, 2022
Next filing
Feb 9, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NKTR Common Stock Sale -$16.3K -5.1K -2.19% $3.19 228K Sep 22, 2022 Direct F1, F2
holding NKTR Common Stock 2.1K Sep 22, 2022 by daughter F3
holding NKTR Common Stock 2.1K Sep 22, 2022 by son F3
holding NKTR Common Stock 2.1K Sep 22, 2022 by daughter F3
holding NKTR Common Stock 28.8K Sep 22, 2022 by Robert Chess Grantor Retained Annuity Trust
holding NKTR Common Stock 28K Sep 22, 2022 by Stacey Chess Grantor Retained Annuity Trust
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was made pursuant to a Rule 10b5-1 trading plan.
F2 This transaction was executed in multiple trades at prices ranging from $3.13 to $3.28. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.
F3 The reporting person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose.